JP2025533334A - ソトラシブ投与レジメン - Google Patents

ソトラシブ投与レジメン

Info

Publication number
JP2025533334A
JP2025533334A JP2025518537A JP2025518537A JP2025533334A JP 2025533334 A JP2025533334 A JP 2025533334A JP 2025518537 A JP2025518537 A JP 2025518537A JP 2025518537 A JP2025518537 A JP 2025518537A JP 2025533334 A JP2025533334 A JP 2025533334A
Authority
JP
Japan
Prior art keywords
cancer
patient
dose
sotorasib
bcrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025518537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025533334A5 (enExample
Inventor
ハウク，ブレット・イー
カルドナ，パンリ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2025533334A publication Critical patent/JP2025533334A/ja
Publication of JP2025533334A5 publication Critical patent/JP2025533334A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2025518537A 2022-09-30 2022-12-16 ソトラシブ投与レジメン Pending JP2025533334A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263411789P 2022-09-30 2022-09-30
US63/411,789 2022-09-30
PCT/US2022/053130 WO2024072437A1 (en) 2022-09-30 2022-12-16 Sotorasib dosing regimen

Publications (2)

Publication Number Publication Date
JP2025533334A true JP2025533334A (ja) 2025-10-06
JP2025533334A5 JP2025533334A5 (enExample) 2026-01-28

Family

ID=85158814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025518537A Pending JP2025533334A (ja) 2022-09-30 2022-12-16 ソトラシブ投与レジメン

Country Status (9)

Country Link
US (2) US20260083741A1 (enExample)
EP (1) EP4593837A1 (enExample)
JP (1) JP2025533334A (enExample)
KR (1) KR20250079183A (enExample)
AU (1) AU2022479909A1 (enExample)
JO (1) JOP20250064A1 (enExample)
MX (1) MX2025003741A (enExample)
TW (1) TW202415380A (enExample)
WO (1) WO2024072437A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013557A (es) * 2021-05-18 2023-11-29 Amgen Inc Pauta posologica de sotorasib.

Also Published As

Publication number Publication date
WO2024072437A1 (en) 2024-04-04
TW202415380A (zh) 2024-04-16
AU2022479909A1 (en) 2025-02-06
KR20250079183A (ko) 2025-06-04
MX2025003741A (es) 2025-05-02
US20260166040A1 (en) 2026-06-18
JOP20250064A1 (ar) 2025-03-25
EP4593837A1 (en) 2025-08-06
US20260083741A1 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
EP1859793B1 (en) Novel combinational use of a sulfonamide compound in the treatment of cancer
EP4340842B1 (en) Sotorasib for use in the treatment of cancer
CN113645975A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
US20220323446A1 (en) Sotorasib dosing regimen
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
CN113423402A (zh) 癌症治疗
JP2026053570A (ja) Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体
CN113645974A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
US20260083741A1 (en) Sotorasib dosing regimen
CA3269092A1 (en) Sotorasib dosing regimen
JP2025535477A (ja) 癌の治療方法
EA053101B1 (ru) Способы лечения рака с помощью соторасиба
HK40111140A (en) Sotorasib and an egfr antibody for treating cancer comprising a kras g12c mutation
CN116981462A (zh) 索托拉西布给药方案
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20250625

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20250625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260120